Prostate Cancer

Cancer is commonly defined as the uncontrolled division of abnormal cells. When cells become aged or damaged, they are replaced with new cells. Sometimes the genetic material (DNA) of a cell can become damaged or altered, producing mutations that negatively affect cell growth and division. Prostate cancer may be slow growing, or it may be aggressive. When confined within the prostate or another organ, cancer is known to be “localized” or “organ-confined”. When cancer cells spread throughout the body (metastasize) via blood and lymph systems, they can become life threatening.

Prostate cancer is one of the leading forms of cancer diagnosed in North American men, typically in men over the age of 50. In its early stages, prostate cancer has no symptoms, which is why it’s important for men to have regular medical checkups. If diagnosed early, prostate cancer is often curable. Treatment can eliminate symptoms and prolong life expectancy.

Prostate_Cancer_pic

Risk Factors

There are several risk factors for prostate cancer, some modifiable, others not. These include:

  • Age – Prostate cancer is most commonly diagnosed in men over the age of 50.
  • Family History – Research shows an increased risk for prostate cancer in sons, brothers and fathers of men with the disease.
  • Genetics – Inherited gene changes may increase prostate cancer risk.
  • Diet – High fat, high calcium and high red meat diets may increase the risk of developing prostate cancer.
  • Ethnicity – Studies have shown that prostate cancer is more common in men of African ethnicity.

For more information about the prostate, visit the Prostate Cancer Canada website.

Russ Greiner’s Team “PC LEARN”, tied for 1st in the Prostate Cancer DREAM Challenge

Competing with 50 teams from around the world in the Prostate Cancer DREAM Challenge, University of Alberta’s PC LEARN team tied for 1st in one of the 3 sub-challenges
to predict the survival and toxicity of Docetaxel treatment in patients with metastatic castrate resistant prostate cancer!

“The DREAM Challenge was an exciting opportunity for us to apply machine learning to real medical data and possibly to contribute to medical research.” said lead PI and APCaRI member Russ Greiner.

The primary benefit of this Challenge will be to establish new quantitative benchmarks for prognostic modeling in mCRPC, with a potential impact for clinical decision making and ultimately understanding the mechanism of disease progression. https://www.synapse.org/#!Synapse:syn2813558/wiki/70844

- Russ Greiner

Our International Network of Partners

Meeting these ambitious goals will not be possible without the committed engagement of our many partners across Alberta, Canada and the World. Learn more about our Partners.